MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Sonoma Pharmaceuticals Cash Conversion Cycle 2011-2026 | SNOA
Annual Cash Conversion Cycle Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 | 173 | 132 | 113 | 80.4 | 107 | 163 | 95.9 | 109 | 69.1 | 66.1 | 86.5 | 54.6 | 74.2 | 84.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 | 54.6 | 104 |
Quarterly Cash Conversion Cycle Sonoma Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95.4 | 121 | - | 147 | 163 | 171 | - | 172 | 161 | 142 | - | 150 | 136 | 89.7 | - | 150 | 38.2 | 50.6 | - | 106 | 102 | 80.7 | 90.5 | 123 | 76.8 | 105 | 83.1 | 122 | 98.3 | 86.5 | - | 102 | 115 | 114 | - | 106 | 38 | 46.2 | - | 112 | 41.2 | 32.8 | - | 67.9 | 24.4 | 36.5 | - | 33.2 | 13.6 | 23.3 | - | 97.1 | 25.8 | 404 | - | 85.8 | 55.8 | 165 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 404 | 13.6 | 100 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 1.19 | 0.85 % | $ 128 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
213 | $ 2.67 | -0.74 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
181 | $ 13.9 | 5.7 % | $ 712 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.68 | 0.6 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
209 | $ 26.0 | 2.73 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | $ 21.5 | - | $ 2.05 B |  France |
 |
Evolus
EOLS
|
74.6 | $ 5.66 | -4.23 % | $ 351 M | USA |
 |
Harrow Health
HROW
|
-86.6 | $ 51.0 | -4.67 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
164 | $ 1.35 | 5.88 % | $ 23.6 M |  China |
 |
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 7.9 | 3.47 % | $ 2.88 B | Canada |
 |
Veru
VERU
|
6.7 | $ 2.37 | 1.72 % | $ 320 M | USA |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
92 | $ 1.1 | -4.35 % | $ 4.74 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 5.19 | 9.96 % | $ 73 M | USA |
 |
Organogenesis Holdings
ORGO
|
64.5 | $ 4.3 | -1.38 % | $ 566 M | USA |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 4.24 | - | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
138 | $ 14.59 | -1.19 % | $ 2 B | USA |
 |
ProPhase Labs
PRPH
|
96 | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
45 | $ 0.95 | 2.78 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
327 | $ 9.43 | -1.05 % | $ 670 M | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.64 | -0.05 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
169 | $ 8.99 | -2.92 % | $ 5.56 B | Canada |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.04 | - | $ 21.3 M | USA |
 |
Viatris
VTRS
|
155 | $ 12.46 | 0.48 % | $ 15.1 B | USA |
 |
Zomedica Corp.
ZOM
|
196 | - | -0.21 % | $ 98 M | USA |